Sorted by New

Topic Contributions


Comments for shorter Cold Takes pieces

Re Omicron-specific boosters -- I'd love some ideas about what to do here.  Orgs like 1DaySooner are helpful for advocacy but I don't see any path to the kind of speed we need here. 

And even Pfizer seems to think that there isn't a reason for urgency right now (WaPo):

“I believe, in principle, we will at a certain time point need a new vaccine against this new variant. The question is how urgent this needs to be available,” CEO Ugur Sahin told a conference hosted by Reuters.

I'm struggling to see a plausible intervention at all here.

(This is Dave Orr, on the board at Packard.)

(Copied from below from before there was this thread.)

Growth and the case against randomista development

Thanks for this very well argued piece.

I think the central claim is that this area is under studied and that we should fund a ~4 person team to investigate more.

Is there a more specific grant proposal available? Or to put it another way, is there a shovel-ready project that we could quickly fund?

Depending on the size and cost of the project, I may be able to help. Happy to continue this conversation over email if you prefer.